REGENXBIO Inc (RGNX) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[3], including 2 Phase 3[1], 2 Phase 2[2].
Trial NCT05693142[4] evaluates RGX-202 in Duchenne Muscular Dystrophy with a target enrollment of 65 participants. Trial NCT03566043[5] evaluates RGX-121 in Mucopolysaccharidosis Type II (MPS II) with a target enrollment of 48 participants.
RGNX has 1 Form 4 insider filing recorded at the SEC in the past 30 days[6].